31 results about "Radiographic Contrast Agent" patented technology

A photoacoustic flow cytometry (PAFC) device for the in vivo detection of cells circulating in blood or lymphatic vessels is described. Ultrasound transducers attached to the skin of an organism detect the photoacoustic ultrasound waves emitted by target objects in response to their illumination by at least one pulse of laser energy delivered using at least one wavelength. The wavelengths of the laser light pulse may be varied to optimize the absorption of the laser energy by the target object. Target objects detected by the device may be unlabelled biological cells or cell products, contrast agents, or biological cells labeled with one or more contrast agents.

Renal extraction fraction (EF) is determined through use of computed tomography (CT) measurements of arterial blood before and after injection of a radiographic contrast agent into the blood and CT measurements of renal vein blood after injection of the radiographic contrast agent.

The present invention relates to a method and nano-sized particles for image guided radiotherapy (IGRT) of a target tissue. More specifically, the invention relates to nano-sized particles comprising X-ray-imaging contrast agents in solid form with the ability to block x-rays, allowing for simultaneous or integrated external beam radiotherapy and imaging, e.g., using computed tomography (CT).

In an X-ray CT apparatus 1 and an X-ray CT method, the thickness of an object to be inspected is computed on the basis of the number of transmitted X-rays in a specific energy range set above and below the K-absorption edge of an X-ray contrast medium serving as the object to be inspected, and a CT image is reconstructed on the basis of the computed thickness of the object to be inspected. Such X-ray CT apparatus 1 and X-ray CT method can generate an X-ray CT image stably and independently of the size of the object to be inspected and of X-ray tube voltage (X-ray energy distribution).

The present invention discloses a radiographic contrasting agent containing multiple aromatic groups, each of which is substituted with at least three halogen atoms. The radiographic contrasting agent can initiate a polymerization process. The present invention also discloses a radio-opaque polymeric material that comprises a biodegradable polymer having at least one radiographic contrasting moiety covalently attached thereto. The radio-opaque polymeric material provides enhanced contrasting intensity in radiographic imaging. The radio-opaque polymeric material can be applied on at least a portion of one surface of a medical device. The radio-opaque polymeric material can also be used to construct a medical device, a component thereof, or a portion of a component thereof.

The present invention discloses a radiographic contrasting agent containing multiple aromatic groups, each of which is substituted with at least three halogen atoms. The radiographic contrasting agent can initiate a polymerization process. The present invention also discloses a radio-opaque polymeric material that comprises a biodegradable polymer having at least one radiographic contrasting moiety covalently attached thereto. The radio-opaque polymeric material provides enhanced contrasting intensity in radiographic imaging. The radio-opaque polymeric material can be applied on at least a portion of one surface of a medical device. The radio-opaque polymeric material can also be used to construct a medical device, a component thereof, or a portion of a component thereof.

A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast agent is characterised in that the contrast component is present in a mixture with at least one further apolar component, the viscosity of which is less than or at most equal to the contrast component viscosity. Methods for angiography examination are also disclosed, in which such a contrast agent or also a polar contrast agent are used at least periodically and applications of such contrast agents.

A radiocontrast agent for tau protein is provided. The agent is selectively and strongly bound to tau protein and its tangle found in brain diseases like Alzheimer's disease (AD). The agent is especially suitable to be used in PET imaging for brain diseases. Or, the agent can be used to inhibit tau protein overexpressive and, thus, stop the proceeding of brain disease.

A magnetic resonance imaging (MRI) methodology is provided for simultaneous measurement of dynamic susceptibility contrast (DSC) MRI and dynamic contrast enhanced (DCE) MRI perfusion and permeability parameters using a combination of dual echo and spiral acquisition techniques with no contrast agent preload. T1 and T2 / T2* leakage effects are eliminated, thereby permitting accurate measurement of blood volume, blood flow and vascular permeability which are used in evaluating tumor angiogenesis.

The present invention discloses an organic radiographic contrasting agent containing an aliphatic or alicyclic backbone and multiple halogen-substituted aromatic groups. Each of the halogen-substituted aromatic groups in the radiographic contrasting agent is substituted with at least three halogen atoms and is covalently attached to the aliphatic or alicyclic backbone. The present invention also discloses a radio-opaque polymeric material comprising the radiographic contrasting agent and at least one polymer. The radiographic contrasting agent is physically admixed with the at least one polymer or physically embedded or dispersed in the at least one polymer. The radio-opaque polymeric material provides enhanced contrasting intensity in radiographic imaging. The radio-opaque polymeric material can be applied on at least a portion of one surface of a medical device. The radio-opaque polymeric material can also be used to construct a medical device, a component thereof, or a portion of a component thereof.

The invention relates to a synthetic method of a non-ionic X-radiographic contrast agent iopamidol impurity C. according to the synthetic method, 5-amino-1,3-dibenzoyl dichloride is used as a starting material. The iopamidol impurity C can provides a qualified reference substance for quality control of iopamidol.

Method for generating contrast agent concentration map from a non-contrast enhanced Computed Tomography scan, a contrast enhanced Computed Tomography scan and corresponding spectral Computed Tomography data, comprising: a. Generating at least two different primary contrast agent concentration maps out of the non-contrast enhanced Computed Tomography scan, the contrast enhanced Computed Tomography scan and the spectral Computed Tomography data, b. Performing a local quality analysis of each primary contrast agent concentration map c. Determining local volumetric weights for each primary contrast agent concentration map based on the local quality analysis, and d. Generating a secondary contrast agent concentration map based on the two primary contrast agent concentration maps and on their corresponding local volumetric weights.

The invention locally delivers a chemotherapeutic or a radiographic contrast agent to an upper tract urothelial carcinoma (UTUC). The invention includes a balloon catheter with a working channel and aballoon placed into the ureter / renal pelvis via retrograde or antegrade ureteral access. The balloon is inflated to temporarily obstruct the ureter, and a formulation with a chemotherapeutic agent isinfused into the working channel of the catheter and allowed to dwell in the ureter / renal pelvis for a time sufficient to allow the formulation to adhere to and penetrate the urothelial wall. The formulations can be liposomal or non-liposomal formulations. At least a portion of the infused chemotherapeutic-agent formulation adheres to the urothelial wall while it is instilled and dwells in the ureter / renal pelvis. The methods of the invention can be performed as an adjuvant therapy to other methods of treating UTUC, including ureteroscopic ablation or resection of the tumor.

The present invention relates to an aptamer that penetrating the blood-brain barrier (BBB), and relates to an application of such an aptamer to a complex combined with a substance that selectively binds to a target substance present in the brain. The aptamer and the complex combined with the aptamer can be used as a positron emission tomography (PET) radiographic contrast agent to diagnose Alzheimer's disease or Parkinson's disease at an early stage. It can be used as a radiographic material that can be imaged on, and can be used as a treatment for degenerative brain diseases.

The present invention discloses an organic radiographic contrasting agent containing an aliphatic or alicyclic backbone and multiple halogen-substituted aromatic groups. Each of the halogen-substituted aromatic groups in the radiographic contrasting agent is substituted with at least three halogen atoms and is covalently attached to the aliphatic or alicyclic backbone. The present invention also discloses a radio-opaque polymeric material comprising the radiographic contrasting agent and at least one polymer. The radiographic contrasting agent is physically admixed with the at least one polymer or physically embedded or dispersed in the at least one polymer. The radio-opaque polymeric material provides enhanced contrasting intensity in radiographic imaging. The radio-opaque polymeric material can be applied on at least a portion of one surface of a medical device. The radio-opaque polymeric material can also be used to construct a medical device, a component thereof, or a portion of a component thereof.

The present invention relates to materials, coatings, apparatus, and methods for removing radiocontrast agent from a patient. In accordance with one aspect of the invention, molecular imprinting technologies are utilized to create a safe, predictable and reliable medium for removal of nephrotoxic contrast agent from body fluids of a patient, such as the bloodstream. In accordance with certain aspects of the present invention, the contrast agent can be removed without mechanical filtering or any other mechanically damaging technique affecting the blood matrix. The molecularly imprinted medium (MIM) can be used to extract the contrast agent from the blood either intra- or extracorporeally.

Improved methods of administration of thiol-based agents, such as NAC (N-acetylcysteine) and STS (sodium thiosulfate), are provided that protect against renal and other organ injury caused by diagnostic or therapeutic intra-arterial procedures which employ radiographic contrast agents.

The present invention relates to compositions and methods for reducing the risk of post-imaging pancreatitis for procedures that employ a radiocontrast medium, particularly procedures that selectively image the pancreas, gallbladder and / or biliary tree. In non-limiting embodiments, the invention provides for a radiocontrast medium comprising: (i) a radiocontrast agent; (ii) a calcineurin inhibitor; and (iii) an antioxidant, and its use in performing imaging of the pancreas and related structures with decreased risk of subsequent pancreatitis relative to conventional radiocontrast agents that lack elements (ii) and (iii).

The present invention generally relates to a process using a mechanochemical approach exploiting the mechanical milling of reactants for the manufacturing of acetyl Iopamidol and, more generally, of key intermediates of radiographic contrast agents, and of the contrast agents themselves.

A glove that is X-ray detectable prepared from a latex formulation comprises a base polymer, an accelerator, a vulcanizing agent, a surfactant, a pH adjuster, an antifoaming agent and a thickener characterized in that the latex formulation further includes radiocontrast filler, wherein the radiocontrast filler comprises a radiocontrast agent, a surfactant, a thickener and a solvent, wherein the radiocontrast filler is used in an amount of at least 10 phr of the latex formulation and wherein the radiocontrast filler has total solid content of 45%.

Renal extraction fraction (EF) is determined through use of computed tomography (CT) measurements of arterial blood before and after injection of a radiographic contrast agent into the blood and CT measurements of renal vein blood after injection of the radiographic contrast agent.

The present invention generally relates to a process using a mechanochemical approach exploiting the mechanical milling of reactants for the manufacturing of acetyl Iopamidol and, more generally, of key intermediates of radiographic contrast agents, and of the contrast agents themselves.

The invention discloses a method of using a ureter double saccule drainage tube. The method comprises the steps that after renal pelvis and renal calyces are dilated through conventional percutaneous hydronephrosis, a guide wire is imported to pass through a ureteral stenosis structure, the ureter double saccule drainage tube is imported through the guide wire; a radiocontrast agent is injected through an external connector of a fork-shaped injection base and is connected with a urine drainage cavity; when the ureteral stenosis structure is at the upper segment of the ureter, the second saccule is located in the ureteral stenosis structure, and the first saccule is located in the ureter; when the ureteral stenosis structure is at the lower segment of the ureter, the first saccule is located in the ureteral stenosis structure, and the second saccule is located in the ureter; the radiocontrast agent is injected through an external connector connected with the first saccule and the external connector connected with the second saccule of the fork-shaped injection base to fill the first saccule and the second saccule; the ureter double saccule drainage tube is fixed on the body surface. The ureter double saccule drainage tube has the advantages of being effective in draining urine, relieving hydronephrosis and expanding continuously the ureteral stenosis structure. The invention also discloses a double saccule drainage tube structure for the method of using the ureter double saccule drainage tube.

In a method and magnetic resonance apparatus to acquire diagnostic image data of a contrast agent-filled target area of a patient, a peak time of the test bolus in the target area is automatically determined, from which a wait period is then determined for administering the main bolus. After the main bolus has been administered to the patient, magnetic resonance images of the target area are acquired, and each is analyzed immediately after acquisition thereof to determine whether that image shows arrival of the contrast agent. If and when one of these images shows such arrival, an acquisition protocol is immediately started in order to acquire the diagnostic image data set. If none of these images shows arrival of the contrast agent, the protocol to acquire diagnostic image data is started after the wait period.

The present invention relates to compositions and methods for reducing the risk of post-imaging pancreatitis for procedures that employ a radiocontrast medium, particularly procedures that selectively image the pancreas, gallbladder and / or biliary tree. In non-limiting embodiments, the invention provides for a radiocontrast medium comprising: (i) a radiocontrast agent; (ii) a calcineurin inhibitor; and (iii) an antioxidant, and its use in performing imaging of the pancreas and related structures with decreased risk of subsequent pancreatitis relative to conventional radiocontrast agents that lack elements (ii) and (iii).

Methods for treating or preventing radiocontrast agent induced kidney injury in a mammal are disclosed, the methods comprising administering to the mammal a first effective amount of a chalcogenide composition prior to administering a radiocontrast agent to the mammal.

The present invention relates to an MRI contrast agent that includes zinc-containing water-soluble metal oxide nanoparticles and has an improved contrast effect. The zinc-containing water-soluble metal oxide nanoparticles are characterized by addition of zinc to a matrix comprising the metal oxide nanoparticles or by substitution of metal in the matrix, resulting in the improved contrast effect of MRI. In addition, the zinc-containing metal oxide nanoparticles of the present invention include the MRI contrast agent t having hybrid structures of “zinc-containing metal oxide nanoparticle—biologically / chemically active material” in which the nanoparticle is conjugated with a bioactive material such as proteins, antibodies, and chemical materials.

Methods for treating or preventing radiocontrast agent induced kidney injury in a mammal are disclosed, the methods comprising administering to the mammal a first effective amount of a chalcogenide composition prior to administering a radiocontrast agent to the mammal.